PITTSBURGH --(BUSINESS WIRE)--Oct. 16, 2020-- Krystal Biotech , Inc. (Nasdaq:KRYS) today announced that Chief Commercial Officer Jennifer Chien is leaving the company, effective today, to pursue another opportunity. Senior members of Krystal’s commercial team will report directly to Chief Executive

- KB301 is designed to deliver a full-length human type 3 collagen transgene via injection - The Phase 1 PEARL-1 clinical study to evaluate KB301 in acne scars and fine wrinkles is currently enrolling PITTSBURGH --(BUSINESS WIRE)--Oct. 8, 2020-- Krystal Biotech , Inc.

PITTSBURGH --(BUSINESS WIRE)--Sep. 24, 2020-- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), a fully integrated gene therapy company driven by its proprietary, engineered herpes simplex virus type 1 vector (HSV-1) platform, today announced that Krish S.

PITTSBURGH , Sept. 09, 2020 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), a fully integrated gene therapy company driven by its proprietary, engineered herpes simplex virus type 1 vector (HSV-1) platform, today announced that Krish S.

KB103 is designed to deliver a full-length human type III collagen transgene via intradermal injection  First in-human study will evaluate the safety and efficacy in acne scars and facial wrinkles Initial data from this study is anticipated in 2021 PITTSBURGH , Aug.

The company is on track to file an IND for KB407 in 2021 PITTSBURGH , Aug. 17, 2020 (GLOBE NEWSWIRE) -- Krystal Biotech , Inc. (Nasdaq:KRYS), a fully integrated gene therapy company driven by its proprietary, engineered herpes simplex virus type 1 vector (HSV-1) platform, today announced that the

Initiated the pivotal GEM-3 clinical study evaluating B-VEC in DEB patients         Today announced enrollment of 1 st patient in Phase 2 clinical study evaluating KB105 in ARCI patients On track to initiate Phase 1 trial of KB301 for an aesthetic indication in 2H 2020         Strong balance sheet

PITTSBURGH , July 30, 2020 (GLOBE NEWSWIRE) -- Krystal Biotech Inc. , (“Krystal”) (NASDAQ: KRYS), a fully integrated gene therapy company driven by its proprietary, engineered herpes simplex virus type 1 vector (HSV-1) platform, today announced that Krish S.

The randomized, double-blind GEM-3 trial will compare repeat dosing of either B-VEC or placebo in approximately 30 dystrophic epidermolysis bullosa (DEB) patients  Top line data and BLA filing are anticipated in 2021; EMA aligned on pivotal study design and an MAA is anticipated shortly after BLA

PITTSBURGH , July 20, 2020 (GLOBE NEWSWIRE) -- Krystal Biotech , Inc. (Nasdaq:KRYS), a fully integrated gene therapy company driven by its proprietary, engineered herpes simplex virus type 1 vector (HSV-1) platform, today announced the appointment of Whitney Ijem to the newly created position of